SCHEMBL5502351

SCHEMBL5502351

[O-][S+](Nc1c[c]ccc1)c1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5549485 0.80 ALDH1A1 (0.39) —
SCHEMBL18034654 0.79 — —
SCHEMBL6990662 0.76 — —
SCHEMBL6973009 0.71 — —
SCHEMBL226139 0.70 HSD17B10 (0.57) —
SCHEMBL23554965 0.68 HPGD (0.48) —
SCHEMBL27449327 0.68 GAA (0.42) —
SCHEMBL11762144 0.68 MAPT (0.48) —
SCHEMBL7090460 0.67 HSD17B10 (0.43) —
SCHEMBL698363 0.67 HTT (0.48) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1776350-A1 NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF ß-SECRETASE ( BACE ) JANSSEN PHARMACEUTICA N.V. (BE) 2007-04-25 — — EP disclosed
WO-2006017844-A1 NOVEL 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) JANSSEN PHARMACEUTICA, N.V. (BE) 2006-02-16 — — WO disclosed
Send feedback